Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 19th of January 2021

Situation Report No. 221 - State of Kuwait 20th of January, 2021




	Glo	bal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	94,124,612	2,034,527	5,382,718	128,644	
New	312,202	8,316	22,214	417	

State of Kuwait

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	158,822	151,936	950	5,936	53	1,415,197
New	578	440	2	=	-	8,845

HIGHLIGHTS

- MoH: 2 Kuwaiti females who came from UK were infected with the new coronavirus variant after another PCR test has been conducted upon arrival.
- MoH continues to advise against travel at the present time.
- Gulf Health Council pubished the gulf guideline for the diagnosis and treatment of COVID-19 guide, the second version (1.1), see link.
- Unicef publishes a "Vaccine Misinformation Management Field Guide", see link.
- WHO provides a practical guide for analysing and using routine data to monitor the effects of COVID-19 on essential health services, see link.
- WHO publishes Interim recommendations for the use of the Pfizer–BioNTech COVID-19 vaccine, under Emergency Use Listing, see link.



IMPORTANT LINKS

- MoH update of COVID-19: https://corona.e.gov.kw/en/
- MoH's link to register for the vaccine:

 $https://cov19 vaccine.moh.gov.kw/SPCMS/CVD_19_Vaccine_RegistrationAr.aspx$


• WHO's COVID-19 weekly situation reports:

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

- WHO's COVID-19 dashboard: https://covid19.who.int/
- GCC guideline for the diagnosis and treatment of COVID-19 guide: http://www.ghc.sa/arsa/Documents/GCC-Screening-and-Diagnostic-Guideline.pdf
- Unicef's Vaccine Misinformation Management Field Guide:

https://www.unicef.org/mena/reports/vaccine-misinformation-management-field-guide

- Analysing and using routine data to monitor the effects of COVID-19 on essential health services: https://www.who.int/publications/i/item/WHO-2019-nCoVessential_health_services-monitoring-2021.1
- Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19



IMPORTANT DEFINITIONS

Who can take the Pfizer-BioNTech COVID-19 vaccine?

According to SAGE (WHO's Strategic Group of Experts on Immunization), the Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective. Nevertheless, there are specific populations for whom vaccination is not recommended for a variety of reasons. These populations currently include people with a history of severe allergies, (particularly it is contraindicated for People with a history of severe allergic reaction to any component of the vaccine), most pregnant women (except for those with unavoidable high risk of exposure such as health workers), international travellers who are not part of a prioritized group (due to limited supplies of the vaccine at present), and children under 16 (due to lack of data). Further studies are needed for immune-compromized persons. The priority is to start vaccinating health workers at high risk of exposure, followed by older adults, before immunizing the rest of the population. For more details see the link



• The National Focal Person is Dr Buthaina AlMudhaf, Assistant Undersecretary, Ministry of Health, email: AlMudhaf@gmail.com

